UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D. C. 20549
____________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act Of 1934
February
28, 2005
Date of
Report (Date of earliest event reported)
___________________________________________________________
ACURA
PHARMACEUTICALS, INC.
(Exact
Name of Registrant as Specified in Charter)
___________________________________________________________
State
of New York |
1-10113 |
11-0853640 |
(State
of Other Jurisdiction |
(Commission
File Number) |
(I.R.S.
Employer |
of
Incorporation) |
|
Identification
Number) |
616
N. North Court, Suite 120
Palatine,
Illinois 60067
(Address
of principal executive offices) (Zip Code)
(847)
705-7709
(Registrant’s
telephone number, including are code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17CFR240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR
240.13e- 4(c))
Item
2.02 Results
of Operations and Financial Condition
On
February 28, 2005, Acura Pharmaceuticals, Inc. (the "Company") issued a press
release disclosing the financial results for its fourth quarter ended December
31, 2004 and the twelve months ended December 31, 2004. A copy of the Company's
press release is attached as Exhibit 99.1 hereto.
Item
9.01 Financial
Statements and Exhibits.
|
Exhibit |
|
|
|
Number |
|
Description |
| |
|
|
| 99.1 |
|
Press
Release dated February 28, 2005 Announcing Results for Fourth Quarter and
Year ended December 31, 2004. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
| |
|
|
| |
ACURA
PHARMACEUTICALS, INC. |
|
|
|
|
By: |
/s/ Peter A. Clemens |
| |
Peter A. Clemens |
| |
Vice President & Chief
Financial Officer |
Date: February
28, 2005
EXHIBIT
INDEX
|
Exhibit |
|
|
|
Number |
|
Description |
| |
|
|
| 99.1 |
|
Press
Release dated February 28, 2005 Announcing Results for Fourth Quarter and
Year ended December 31, 2004. |